## DEPARTMENT OF STATE HEALTH SERVICES

## CENTRAL OFFICE INSTITUTIONAL REVIEW BOARD APPLICATION FOR CONTINUING REVIEW OR STUDY CLOSURE

			Protocol #:	
Proj	ect Title:			
Prin	cipal Investigator(s): (Give	address for correspondence	e about approval.)	
(Na	me type or print)	Address	E-mail	l Address
If fu	nded, indicate title of grant	and funding agency:		
Date	of initial IRB review:	Date of last IF	RB review:	
revierega plan resea perio	ew must take place on or be rdless of when the research ned changes in the protoco arch participants. Please co od following your last IRB	earch Proposal (See Section	iry of the previous IRB igators must also repor may affect the protection they apply to your pro	review, t to the IRB any ion of human ject during the
1.	Has the research begun?		Yes	No
2.	Enrollment of subjects or	ngoing?	Yes	No
3.	Date that first subject was			
4.				
	Number actually enrolled			
	Number of subjects enrol	led in the past 12 months:		
	Number withdrew or drop	oped out:		
	Number dropped out beca (Explain in #9)	ause of adverse study events	:	
5.	Study interventions ongo: (e.g. Surveys, questions	_	Yes	No
6.	Is this a Final Report? (Protocols can be inactive activities, including data)	ated when all research analysis, have been complete	Yes ed).	No

7.	informed Consent:	37	NT			
	Was consent obtained for all subjects?	Yes	No			
	Did all subjects receive a copy of the signed consent form?	Yes	No			
	Where are signed consent forms stored?	(Cital Dida an	d soom nymbos			
	D'1 11 11 11 11 11 11 11 11 11 11 11 11 1		d room number			
	Did you encounter any problems in obtaining consent?  If yes, please describe:	Yes	No			
	Is the person obtaining consent approved by the IRB?		No			
	If no, please describe:		110			
8.	Have any changes been made to the following:					
0.	Protocol?	Yes	No			
	Consent?	Yes	No			
	Questionnaires?	Yes	No			
	Study Interventions?	Yes	No			
	New Investigators?	Yes	No			
	If yes to any of above, please describe on a separate sheet.		1,0			
9.	Has any new scientific information (such as recently identified risks of participating in					
· .	research of this type or new treatment/alternative approaches been found) since the last IR					
	approval?	Yes	No			
	If yes, please describe on a separate sheet this new informat in your study may be affected by these findings.	ion and how the	risk to subjects			
10.	During the past 12 months please indicate the following:					
	Number of serious adverse events:					
	Number of deaths:					
	Were the events listed above promptly reported to the IRB?	Yes	No			
	If no, please explain:					
11.	. Summarize Study Activities and Findings to Date. (Attach	resulting public	ations).			
I/we	certify that the statements and attachments concerning this re	esearch are true				
	Signature of Principal Investigator	Date	<u> </u>			
	Signature of Finnespur Investigation	2				
REV	IEWED and APPROVED:					
The	information provided has been reviewed and approved by the	DSHS Central	Office			
	tutional Review Board (CO-IRB) for the Protection of Huma					
	pliance with federal regulations for continuing review.	·				
	Signature of IRB Chair or Acting Chair	Date of Re	view			